PMID- 31629917
OWN - NLM
STAT- MEDLINE
DCOM- 20200416
LR  - 20200416
IS  - 1879-0720 (Electronic)
IS  - 0928-0987 (Linking)
VI  - 141
DP  - 2020 Jan 1
TI  - Novel radiopharmaceutical (Technetium-99m)-(DOTA-NHS-ester)-Methionine as a 
      SPECT-CT tumor imaging agent.
PG  - 105112
LID - S0928-0987(19)30385-9 [pii]
LID - 10.1016/j.ejps.2019.105112 [doi]
AB  - Breast cancer is the most common type of cancer in women worldwide. There have 
      been many efforts for early breast cancer detection and among them molecular 
      imaging have been extremely of high importance. Single-photon emission computed 
      tomography (SPECT/CT) is a kind of imaging technique able to reveal crucial 
      information with using radiopharmaceuticals. In this study, 
      Technetium-99m-(DOTA-NHS-ester)-Methionine radiopharmaceutical was synthesized. 
      Between 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 
      mono-N-hydroxysuccinimide ester (DOTA-HNS ester) (MACROCYCLICS, DOTA-NHS ester, 
      Plano, Texas, USA) and methionine(marker) were conjugated. The DOTA-HNS 
      ester-Methionine was labeled with Technetium-99m (Inter-Medical, Technetium-99m, 
      Bergamo, Italy). The synthesized radiopharmaceutical was used in SPECT/CT imaging 
      for breast cancer diagnosis. For radiopharmaceutical evaluation, MTT assay for 
      cellular toxicity, biodistribution, cellular uptake and radiochemical purity were 
      employed.Technetium-99m-(DOTA-NHS-ester)-Methionine radiochemical had less 
      cellular toxicity in human embryonic kidney cells 293 cell line (HEK293). 
      Cellular uptake was indicated higher percent with use of Methionine as a marker, 
      and radiochemical purity was high. Based on the results 
      Technetium-99m-(DOTA-NHS-ester)-Methionine radiochem may be a better option for 
      early detection of breast cancer. Further study is recommended to confirm these 
      findings in clinical practice.
CI  - Copyright (c) 2019. Published by Elsevier B.V.
FAU - Mojarrad, Paria
AU  - Mojarrad P
AD  - Faculty of Pharmacy, International Campus, Tehran University of Medical Sciences 
      International Campus (TUMS-IC), Tehran, Iran.
FAU - Zamani, Saeedeh
AU  - Zamani S
AD  - Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Seyedhamzeh, Mohammad
AU  - Seyedhamzeh M
AD  - Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran. Electronic address: m.s.hamzeh@gmail.com.
FAU - Omoomi, Farnoor Davachi
AU  - Omoomi FD
AD  - Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran.
FAU - Karimpourfard, Naeim
AU  - Karimpourfard N
AD  - Faculty of Pharmacy, International Campus, Tehran University of Medical Sciences 
      International Campus (TUMS-IC), Tehran, Iran.
FAU - Hadadian, Shahin
AU  - Hadadian S
AD  - Nano-Biotechnology Department of Pasteure Institute of Iran, Tehran, Iran.
FAU - Ebrahimi, Seyed Esmadeil Sadat
AU  - Ebrahimi SES
AD  - Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Hamedani, Morteza Pirali
AU  - Hamedani MP
AD  - Department of Medicinal Chemistry, Faculty of Pharmacy, Tehran University of 
      Medical Sciences, Tehran, Iran.
FAU - Farzaneh, Jafar
AU  - Farzaneh J
AD  - Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran. Electronic address: jafarfarzaneh97@gmail.com.
FAU - Ardestani, Mehdi Shafiee
AU  - Ardestani MS
AD  - Department of Radiopharmacy, Faculty of Pharmacy, Tehran University of Medical 
      Sciences, Tehran, Iran. Electronic address: shafieeardestani@tums.ac.ir.
LA  - eng
PT  - Journal Article
DEP - 20191017
PL  - Netherlands
TA  - Eur J Pharm Sci
JT  - European journal of pharmaceutical sciences : official journal of the European 
      Federation for Pharmaceutical Sciences
JID - 9317982
RN  - 0 (Contrast Media)
RN  - 0 (DOTA-NHS)
RN  - 0 (Esters)
RN  - 0 (Radiopharmaceuticals)
RN  - 0 (Succinimides)
RN  - 7440-26-8 (Technetium)
RN  - AE28F7PNPL (Methionine)
SB  - IM
MH  - Animals
MH  - Biological Transport
MH  - Cell Survival/drug effects
MH  - Contrast Media/*administration & dosage/pharmacokinetics
MH  - Esters
MH  - HEK293 Cells
MH  - Humans
MH  - MCF-7 Cells
MH  - Male
MH  - Methionine/*administration & dosage/pharmacokinetics
MH  - Mice
MH  - Neoplasms/metabolism
MH  - Radiopharmaceuticals/*administration & dosage/pharmacokinetics
MH  - Succinimides/*administration & dosage/pharmacokinetics
MH  - Technetium/*administration & dosage/pharmacokinetics
MH  - Tissue Distribution
MH  - Tomography, Emission-Computed, Single-Photon
OTO - NOTNLM
OT  - 99mTc
OT  - Biodistribution
OT  - DOTA-NHS
OT  - Imaging
OT  - Methionine
OT  - SPECT
EDAT- 2019/10/21 06:00
MHDA- 2020/04/17 06:00
CRDT- 2019/10/21 06:00
PHST- 2019/06/25 00:00 [received]
PHST- 2019/10/14 00:00 [revised]
PHST- 2019/10/16 00:00 [accepted]
PHST- 2019/10/21 06:00 [pubmed]
PHST- 2020/04/17 06:00 [medline]
PHST- 2019/10/21 06:00 [entrez]
AID - S0928-0987(19)30385-9 [pii]
AID - 10.1016/j.ejps.2019.105112 [doi]
PST - ppublish
SO  - Eur J Pharm Sci. 2020 Jan 1;141:105112. doi: 10.1016/j.ejps.2019.105112. Epub 
      2019 Oct 17.